# GILUPI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gilupi

- Industry: Medical Devices & Equipment
- Headquarters: Potsdam, Germany
- Website: www.gilupi.com
- Total disclosed funding: $7.2M
- Latest round: Series C (Jan 13, 2011)
- Investors on record: 4

## About

GILUPI GmbH develops advanced medical technology, focusing on innovative diagnostic solutions for personalized cancer treatment, leveraging proprietary methods to enhance cancer diagnostics and patient-specific therapies.Founded in 2006 in Potsdam, Germany, GILUPI GmbH specializes in medical technology aimed at improving cancer diagnostics. The company has undergone significant funding since its inception and has successfully raised EUR 3.60 mn through its latest round, the Series C, completed in December 2016, with investors including Aurelia Private Equity and Brandenburg Kapital. The total amount raised by the company amounts to EUR 3.60 mn, resulting in a current valuation of EUR 75.56 mn. Christian Jurinke serves as the CEO.GILUPI GmbH specializes in developing innovative medical technology and diagnostic solutions aimed at personalized cancer medicine. Its core product, the GILUPI CellCollector®, isolates circulating tumor cells directly from the bloodstream, enabling in vivo analysis through liquid biopsy. This non-invasive technique allows healthcare professionals to conduct specific cancer diagnostics and tailor treatment plans based on individual patient profiles. The GILUPI CellCollector® has been certified for clinical applications and has been utilized in over 14,000 procedures, primarily serving hospitals, diagnostic laboratories, and oncology centers across markets in Germany, France, and parts of Asia.For the most recent year in 2021, GILUPI GmbH reported a revenue of EUR 1,316,353.70. The company's business model is primarily B2B, engaging with healthcare institutions and laboratories that utilize its diagnostic products and services, generating revenue through direct sales of the GILUPI CellCollector® and associated services.GILUPI GmbH aims to expand its market presence by launching new products designed to enhance cancer diagnostics. The company is exploring opportunities to enter new geographic markets, particularly in Europe and Asia, by leveraging its recent funding from the Series C round to support these initiatives. The funding will facilitate the development of additional diagnostic technologies and improve operational capabilities to meet the growing demand in oncology. The company is also focused on enhancing its existing product offerings to sustain long-term partnerships with healthcare institutions.

## Funding rounds

- Series C, Jan 13, 2011, $4.7M — Aurelia Private Equity, High-Tech Gruenderfonds, Brandenburg Kapital
- Seed, Oct 26, 2006, $2.5M — Aurelia Private Equity, High-Tech Gruenderfonds, Brandenburg Kapital, S-UBG Gruppe

## Investors

- Aurelia Private Equity (https://capitalatlas.ai/funds/aurelia-private-equity) — Seed, Series C
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series C
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Seed, Series C
- S-UBG Gruppe (https://capitalatlas.ai/funds/s-ubg-gruppe) — Seed